质子抑制剂处方行为的决定因素和干预措施:一个系统的范围审查
L C van Gestel1, M A Adriaanse2,3, S L Kanis3
1Health, Medical and Neuropsychology Unit, Leiden University, Leiden, The Netherlands. l.c.van.gestel@fsw.leidenuniv.nl.
BMC primary care
|June 11, 2024
概括
不适当地处方质子抑制剂 (PPI) 是常见的. 专注于赋能的干预措施,如药剂师参与,持续改善PPI处方,与单独的教育不同.
科学领域:
- 药理学 药理学是指药理学的学科.
- 行为科学 行为科学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 质子抑制剂 (PPI) 被广泛使用,通常没有明确的说明.
- 长期使用PPI具有风险,需要解决不适当的处方模式.
研究的目的:
- 为了确定PPI处方的决定因素.
- 审查修改PPI处方行为的策略.
- 评估干预措施是否解决了关键的处方决定因素.
主要方法:
- 在八个数据库中进行系统的文献搜索,寻找PPI处方决定因素的研究.
- 包括西方国家对成人口服PPI的研究.
- 以行为变化轮框架为指导的分析.
主要成果:
- 包括74篇论文,重点是关于后果作为决定因素的知识和信念.
- 关于后果的信念始终影响着PPI的处方;知识产生了混合的结果.
- 启用策略 (例如,算法,药剂师参与) 改善了处方,而教育显示出混合的有效性.
结论:
- 目前的研究过度强调在PPI处方中进行反思性决策.
- 未来的干预措施应针对反射和冲动行为决定因素,以提高有效性.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
376
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
376
Peptic Ulcer Disease IV: Management
87
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
378
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
378
Peptic Ulcer Disease I: Introduction
163
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
163
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
425
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
425
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
363
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
363


